01 / CAPSID
AAV capsid engineering and selection
Select or engineer capsids matched to human neuronal subtypes, supported by a broad library of wild-type and engineered serotypes.
AAV Serotype Selection Resource
AAV Serotype Selection Guide for Human iPSC-Derived Neuronal Models
AAV is a leading platform for neuroscience gene delivery, but its performance is not universal. Systematic screening across human iPSC-derived neurons shows that AAV6, AAV6.2, and AAV2.7m8 broadly transduce human cortical, NGN2-induced, and dopaminergic neurons—while AAV2-retro stands out for dopaminergic subtypes—offering an empirical, human-relevant starting point for capsid selection.
01 Does mouse data transfer? No—AAV tropism is species-dependent and must be validated in human models.
02 Which serotypes transduce broadly? AAV6, AAV6.2, and AAV2.7m8 lead in human iPSC-derived neurons.
03 What about dopaminergic neurons? AAV2-retro shows strong transduction in DA subtypes.
04 Is more expression better? Balance efficiency against neuronal health, especially in fragile NGN2 neurons.
Direct Answer
Rodent AAV data does not predict human neurons
Many widely used CNS capsids—including AAV9, AAV-PHP.eB, and AAV-PHP.S—were optimized in rodents. AAV-PHP.B-family capsids achieve their remarkable mouse CNS tropism through the mouse-specific host factor LY6A, a mechanism that does not translate to primates. Selecting a serotype purely on mouse data therefore risks weak expression and inconsistent results in human systems.
Human iPSC-derived neurons and brain organoids provide a human-genetic-background platform to evaluate tropism, expression, toxicity, and therapeutic feasibility before committing to complex preclinical systems.
The key principle: choose serotypes on empirical, human-model data and validate them in your intended system—never assume a rodent-validated capsid transfers to human neurons.
Wrong Serotype
Inefficiency forces higher doses
A low-efficiency serotype demands higher doses, increasing cellular stress, toxicity, and experimental cost.
Uncontrolled Expression
Overexpression creates artifacts
Excess expression can produce artificial phenotypes unrelated to the biological question under study.
Species Mismatch
Mouse-optimized capsids fail
Capsids selected in rodents may fail in human neurons, producing weak or inconsistent expression.
Toxicity Trade-off
Efficiency is not always safe
The most efficient capsid may also be the most toxic to a fragile neuronal subtype, so health must be measured alongside expression.
Screening Results
Serotype candidates for human iPSC-derived neurons
A systematic screen of 18 wild-type and engineered serotypes across human cortical, NGN2-induced, and dopaminergic neurons identified a short list of broadly efficient candidates and one subtype-biased performer.
| Serotype | Profile in human iPSC-derived neurons | Best use |
|---|---|---|
| AAV6 | Broad transduction across multiple neuronal subtypes | General transgenic expression and reporter delivery |
| AAV6.2 | Particularly strong in cortical and dopaminergic neurons | High-efficiency expression in key neuronal subtypes |
| AAV2.7m8 | Excellent across models; validated from organoid surface to core | Organoids, neuronal labeling, CRISPR delivery, disease modeling |
| AAV2-retro | Strong, DA-neuron-biased transduction | Dopaminergic-neuron and Parkinson's disease applications |
| AAV9 / PHP.eB / PHP.S | Relatively weak in these human models despite rodent performance | Validate in human systems before relying on them |
AAV2.7m8 has been independently confirmed in peer-reviewed human brain organoid studies, and its GFP signal reaches from the surface to the core of organoids, supporting broad applicability in human CNS models.
Selection Strategy
A practical serotype selection workflow
Select serotypes for the target cell type and the experimental goal, validate empirically, and keep neuronal health in view.
-
01
Start Human-Relevant
Prefer serotypes with proven human-cell performance, such as AAV6, AAV6.2, and AAV2.7m8.
-
02
Match Subtype Needs
Consider AAV2-retro for dopaminergic-neuron applications, then verify specificity.
-
03
Titrate the Dose
Test multiple dose gradients to find the lowest effective dose that preserves health.
-
04
Validate & Confirm
Validate in your 2D or 3D system and confirm findings with molecular and functional assays.
Efficiency vs. Toxicity
Balance transduction efficiency with neuronal health
The strongest-expressing serotype is not always the best choice. Different neuronal subtypes tolerate expression differently, so dose and design must be matched to cell type.
Subtype Sensitivity
Dopaminergic neurons are relatively tolerant; cortical neurons are moderately sensitive; NGN2-induced neurons are the most fragile.
Lowest Effective Dose
Aim for sufficient expression at the minimum dose, rather than maximizing expression indiscriminately.
Promoter Choice
Prefer cell-type-appropriate specific promoters over unnecessary ubiquitous strong promoters.
Paired Controls
Use control and empty-vector groups to separate transgene effects from vector effects.
Vector Quality
Low endotoxin, low aggregation, and high purity matter most in sensitive neuronal systems.
Orthogonal Confirmation
Confirm key findings with immunostaining, qPCR, Western blot, or electrophysiology.
Decision Framework
Matching serotype to application
The right capsid depends on what you are delivering and to which cell type. These rules route each goal to the most promising starting point.
General transgenic expression
Choose: AAV6, AAV6.2, or AAV2.7m8 for broad neuronal transduction.
Use case: reporter delivery, neuronal labeling, and overexpression studies.
Dopaminergic-neuron research
Choose: AAV2-retro for its strong DA-neuron transduction, with validation.
Use case: Parkinson's disease modeling and therapeutic rescue studies.
Organoid and 3D transduction
Choose: AAV2.7m8, validated across organoid surface and core.
Use case: brain organoid transduction and disease model perturbation.
Fragile or sensitive neurons
Choose: the lowest effective dose with a matched promoter, not the strongest serotype.
Use case: NGN2-induced and other high-expression-sensitive models.
Selection Outputs
From screening to a validated vector
Each selection decision maps to a deliverable that de-risks downstream biology.
Validated serotype
Empirically matched to your model.
Optimized dose
Lowest effective, health-preserving dose.
Health readouts
Efficiency measured alongside viability.
QC-backed vector
Low endotoxin, characterized capsid.
From Question to Evidence
Creative Biolabs Support
Creative Biolabs can help you select, produce, and characterize the right AAV for human neuronal models, from capsid choice through QC-backed production.
02 / DESIGN
Vector design for neuroscience
Design constructs with appropriate promoters and payloads for expression, knockdown, CRISPR delivery, and disease modeling.
03 / PRODUCTION
QC-backed AAV production
Produce low-endotoxin, low-aggregation, characterized AAV suitable for sensitive neuronal and organoid systems.
04 / TITRATION
Titer and characterization
Confirm genome titer and quality so that dose-response and serotype comparisons are not confounded by vector quality.
05 / NEURO PLATFORM
iPSC and organoid neuroscience
Leverage iPSC-derived neurons and organoid platforms to evaluate vector performance in a human cellular context.
Selected Reading
Scientific and regulatory context
Serotype Screening
Wiora L, et al. Comprehensive investigation of AAV tropism across human iPSC-derived neuronal subtypes. bioRxiv. 2026. https://doi.org/10.64898/2026.03.24.713895.
Species-Specific Tropism
Hordeaux J, et al. The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier. Molecular Therapy. 2019;27(5):912–921. https://doi.org/10.1016/j.ymthe.2019.02.013.
Human CNS Tropism
Nonnenmacher M, Wang W, Child MA, Ren XQ, Huang C, Ren Z, et al. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Molecular Therapy - Methods & Clinical Development. 2021;20:366–378. https://doi.org/10.1016/j.omtm.2020.12.006.
FAQ
AAV serotype selection for iPSC neurons
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
